Abby Housman
Family Medicine · Chickasha, OKNPI 1023336542
Payments from drug & device makers
Across 118 payments — averaging $15.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$293
- GSK$195
- Bayer$157
- Johnson & Johnson$143
- Abbott$111
- AbbVie$101
- plus $874 from 24 others
What the payments were for
- Food & beverage$1,874100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 18 | $293 |
| GSK | 12 | $195 |
| Bayer | 9 | $157 |
| Johnson & Johnson | 10 | $143 |
| Abbott | 7 | $111 |
| AbbVie | 5 | $101 |
| Sumitomo Pharma America, Inc. | 5 | $100 |
| Sanofi-aventis U.S. LLC | 6 | $90 |
| Boehringer Ingelheim | 5 | $79 |
| Novartis | 4 | $73 |
| Lilly USA, LLC | 5 | $63 |
| AstraZeneca | 3 | $50 |
| Sunovion Pharmaceuticals Inc. | 7 | $48 |
| Amgen | 2 | $47 |
| Pfizer | 3 | $43 |
| Astellas Pharma US Inc | 2 | $34 |
| Dexcom, Inc. | 2 | $31 |
| Abiomed | 1 | $28 |
| Medtronic | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Nevro Corp. | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Merck | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Therapeuticsmd, Inc. | 1 | $14 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
| Pernix Therapeutics Holdings, Inc. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$1,874 in reported general payments places this provider in the 70th percentile of 1,730 family medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 120 | $134,715 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 104 | $99,254 |
| TrulicityDulaglutide | 94 | $97,303 |
| EliquisApixaban | 124 | $79,623 |
| JardianceEmpagliflozin | 66 | $71,060 |
| MounjaroTirzepatide | 28 | $43,072 |
| JanuviaSitagliptin Phosphate | 49 | $30,816 |
| XareltoRivaroxaban | 44 | $27,028 |
| MyrbetriqMirabegron | 50 | $25,037 |
| LinzessLinaclotide | 15 | $20,044 |
| FarxigaDapagliflozin Propanediol | 20 | $15,558 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $12,044 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $9,774 |
| EntrestoSacubitril/Valsartan | 14 | $8,114 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $7,457 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $63 | $140,375122 claims |
| Novo NordiskOzempic | $293 | $134,715120 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $195 | $112,009140 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta | $79 | $89,665103 claims |
| PfizerEliquis | $43 | $79,623124 claims |
| Johnson & JohnsonXarelto, Invega | $143 | $31,28267 claims |
| MerckJanuvia | $16 | $30,81649 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $50 | $29,51857 claims |
| Astellas Pharma US IncMyrbetriq | $34 | $25,03750 claims |
| AbbVieLinzess | $101 | $20,04415 claims |
| NovartisEntresto | $73 | $8,11414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Chickasha
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.